Sustained-Release Buprenorphine Formulation for Opioid Use Disorder
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for opioid use disorder often fail to provide sustained opioid blockade, leading to continued craving and misuse of illicit opioids, with existing formulations requiring frequent dosing and resulting in suboptimal therapeutic steady-state buprenorphine plasma concentrations.
Innovation Solution
Development of sustained-release buprenorphine formulations administered monthly, which achieve therapeutic plasma concentrations that maintain opioid blockade, reduce craving and withdrawal symptoms, and prevent misuse by ensuring consistent mu-opioid receptor occupancy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent dosing is used with existing formulations, then opioid blockade can be maintained, but treatment compliance deteriorates and patient burden increases
Solution Approach 1:
The extended-release formulation segments the drug release process into controlled phases, delivering buprenorphine at optimized intervals that maintain therapeutic effectiveness while reducing dosing frequency from multiple times daily to once daily or less frequent dosing
Solution Approach 2:
The formulation ensures continuous opioid blockade by maintaining steady buprenorphine plasma concentrations through extended-release mechanisms, eliminating gaps in therapeutic action that occur with frequent dosing regimens and improving patient compliance
2Reliability
If higher buprenorphine doses are administered, then opioid blockade effectiveness improves, but risk of misuse and diversion increases
Solution Approach 1:
The formulation changes the pharmacokinetic parameters of buprenorphine delivery, achieving effective opioid blockade through optimized release rates and plasma concentration profiles rather than simply increasing total dose, thereby maintaining effectiveness while reducing abuse potential
Solution Approach 2:
The extended-release formulation creates a single-use or limited-use dosing regime where each administered unit provides prolonged therapeutic action, reducing the number of dispensing events and opportunities for diversion while maintaining adequate blockade effectiveness
3Ease of operation
If sustained-release formulations are developed, then dosing frequency is reduced, but achieving therapeutic steady-state plasma concentrations becomes more difficult
Solution Approach 1:
The formulation employs dynamic release mechanisms that adapt buprenorphine release rates to maintain steady plasma concentrations, using pH-dependent or enzyme-triggered release profiles that optimize drug delivery throughout the dosing interval to achieve and maintain therapeutic levels
Solution Approach 2:
The extended-release formulation incorporates feedback mechanisms through its release kinetics, where the drug release rate responds to physiological conditions and plasma concentration levels, automatically adjusting to maintain therapeutic steady-state concentrations without requiring precise manual dosing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monthly dosing regimens of sustained-release buprenorphine formulations effectively control craving and withdrawal symptoms, prevent illicit opioid use, and enhance treatment concordance by maintaining therapeutic plasma levels and receptor occupancy, thereby reducing the need for rescue medications and minimizing misuse.
Implementation Method 1
By binding to μ-opioid receptors in the brain, buprenorphine reduces craving for opioids and opiate withdrawal symptoms
Data Source
AI summary
The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.